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Abstract
The diagnosis of primary Sjögren’s syndrome (pSS) is complex, and the saliva test is a potential method to im-
prove the existing diagnostic criteria.
Objective: To estimate the diagnostic accuracy of salivary anti-SSA/B antibodies in primary Sjögren’s syndrome 
(pSS), and to analyze their correlations with clinical and laboratory profiles. 
Study Design: This study enrolled 100 pSS patients and 140 non-pSS controls, including 40 rheumatoid arthritis 
(RA) patients, 40 systemic lupus erythematosus (SLE) patients, and 60 healthy controls. Unstimulated whole sa-
liva and stimulated parotid saliva samples were collected from the subjects. Salivary anti-SSA/B antibodies were 
measured using an enzyme-linked immunosorbent assay (ELISA). Clinical and laboratory data were retrieved 
from the medical records. 
Results: In the pSS group, the sensitivity of anti-SSA and anti-SSB antibodies in whole saliva was 49% and 29%, 
respectively, and the specificity was 87.5% and 95%. The sensitivity of anti-SSA and anti-SSB antibodies in pa-
rotid saliva was 32% and 8%, respectively, and the specificity was 95.52% and 97.86%, respectively. In the pSS 
group, the diagnostic accuracy of anti-SSA/B antibodies in whole saliva was significantly higher than in parotid 
saliva (p<0.05), but was significantly lower than in serum (p<0.05). The salivary flow rate in the pSS group posi-
tive for whole salivary anti-SSA was significantly lower than in the negative group (p<0.05). The prevalence of 
rheumatoid factor and antinuclear factor were significantly higher in salivary SSB-positive pSS patients than in 
SSB-negative patients (p<0.05). 
Conclusions: Compared to parotid saliva, whole saliva is a more suitable diagnostic fluid. Using salivary anti-
SSA/B antibodies as a single test item is insufficient given the relatively low sensitivity. Further studies should in-
vestigate the possibility of combining tests for different salivary autoantibodies as a method for diagnosing pSS.
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Introduction 
Sjögren’s syndrome (SS) is an autoimmune disease, 
characterized by lymphocytic infiltration and the de-
struction of exocrine glands, and resulting in a dry 
mouth (xerostomia) and dry eyes (xerophthalmia) (1). 
Exocrinopathy can occur alone as primary Sjögren’s 
syndrome (pSS) or in association with other autoim-
mune disorders (secondary SS), including rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE) 
(2,3). Given the absence of gold standard diagnostic cri-
teria, the early diagnosis and treatment of this disease is 
difficult (4,5). The diagnosis requires interdepartmental 
cooperation, including an assessment of salivary gland 
function, ophthalmological examination, serological 
tests, and a labial salivary gland biopsy. The serologi-
cal test for SSA/B is usually indispensable, but is an 
invasive test.
Anti-SSA antibodies were initially found in patients with 
SS (6). They are among the antinuclear autoantibodies 
(ANA) detected most frequently, not only in SS, but also 
in other systemic autoimmune diseases, such as SLE, 
systemic sclerosis (SSc), myositis, and sometimes RA 
(7). Anti-SSA antibodies are detectable in 63% of pSS 
serum samples and in 46% of SLE samples (8), compared 
to only 3-15% of RA patients and 3-11% of SSA-positive 
SSc patients (9). There is a strong association between 
anti-SSA and anti-SSB antibodies. Anti-SSA can be 
found alone in many sera, while anti-SSB antibodies are 
usually accompanied by anti-SSA (10).
Recent studies have indicated that saliva obtained from 
SS patients can be tested for autoantibodies (11,12). How-
ever, the role that saliva autoantibodies play in the diag-
nosis of SS, the parallel relationship between saliva and 
serum autoantibodies, and their correlations with clinical 
manifestations remain unclear. This study investigated 
the salivary anti-SSA/B autoantibody levels in pSS pa-
tients and explored their value in the diagnosis of pSS.
Material and Methods
The study participants were enrolled from the outpa-
tient clinics of the Department of Oral Medicine, Peking 
University Stomatology Hospital, and the Department 
of Rheumatology & Immunology, Peking University 
People’s Hospital from 2007 to 2012. All of the pSS pa-
tients were diagnosed according to the revised interna-
tional classification criteria (2002) for SS (13). In total, 
100 pSS patients were recruited into the experimental 
group (95 females, 5 males; average age 54.23±13.44 
years). The control group comprised 60 healthy indi-
viduals (43.2±11.00 years), 40 RA patients (53.3±11.28 
years), and 40 SLE patients (40.9±11.32 years). The age 
and gender of the pSS and control groups were both 
matched. All of the SLE and RA patients were diag-
nosed according to the American College of Rheuma-
tology (ACR) criteria for the classification of SLE (14) 
and RA (15), respectively. All of the study subjects gave 
informed consent before participating. Potential sub-
jects were excluded if they smoked, had taken antibi-
otics, antifungals, or immunosuppressants within the 
previous 2 weeks, had a history of head/neck radiation 
or chemotherapy, hepatitis C virus (HCV) or human 
immunodeficiency virus (HIV) infection, lymphoma, 
amyloidosis, sarcoidosis, or graft-versus-host disease, 
or had taken anticholinergic drugs (e.g., atropine, hyo-
scyamine, propantheline bromide, belladonna).
Unstimulated whole saliva (WS) and parotid saliva (PS) 
samples were collected from all participants. The sub-
jects were instructed to stop eating and drinking for 2 h 
before saliva collection. All collections were performed 
by the same dentist, in one place between 9:00 and 
11:00 a.m., under similar light and temperature condi-
tions. Before sampling, the participants were instructed 
to rinse orally for 1 min and to rest for 5 min. The WS 
was collected over at least 15 min and then centrifuged 
at 2600 × g for 15 min at 4°C. The supernatant was sep-
arated and stored at -80°C until subsequent use. Parotid 
saliva was collected using modified Carlson-Crittenden 
cups, which consist of two concentric circles of differ-
ent diameters. A cup was placed over the buccal mem-
brane during collection with the inner sucker aligned 
with the parotid duct orifice. Then, the suction cup was 
fixed to the buccal membrane by sucking the air out of 
the outer sucker. The PS was collected over a period of 
at least 15 min.
The salivary anti-SSA/B antibodies were tested us-
ing anti-SSA/B enzyme-linked immunosorbent assay 
(ELISA) immunoglobulin G (IgG) kits (EUROIM-
MUN, Lubeck Germany). The saliva samples were di-
luted 1:50 in phosphate-buffered saline (PBS), and 100 
μL the diluent were used for the ELISA. The optical 
density (OD) was measured at 492 nm using an ELISA 
spectrophotometer (Bio-Rad Model 550; Microplate 
Reader, Hercules, CA, USA). Each sample was tested in 
triplicate. Positive values were defined as values great-
er than two standard deviations from the average OD 
measured in the control group.
Clinical and laboratory data were retrieved from the 
clinical records of all participants. The clinical infor-
mation included age, gender, symptoms of dry mouth 
and dry eyes, results of Schirmer’s test, tear film break-
up test, corneal staining test, parotid gland sialography, 
and labial salivary gland biopsy, and a history of other 
connective tissue diseases. The laboratory data retrieved 
included the serum anti-SSA/B, ANA, rheumatoid fac-
tor (RF), and IgG.
Data were analyzed using the SPSS 13.0 statistical soft-
ware package. For dichotomous data, Pearson’s test and 
the McNemar test were used. For continuous data the 
t-test was used. P values less than 0.05 were considered 
statistically significant.
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Results
1. General information of the participants.
Totally 100 pSS patients were recruited into experi-
mental group, 95 female and 5 male, with an average 
age of 54.23±13.44 years old. Sixty healthy individu-
als, forty rheumatoid arthritis (RA) patients and forty 
systemic lupus erythematosus (SLE) patients were en-
rolled in control group, with average ages of 43.2±11.00, 
53.3±11.28 and 40.9±11.32 years old, respectively. The 
age and gender were both matched between pSS group 
and control group. 
2. Sensitivity and specificity of anti-SSA/B antibodies
in whole and parotid saliva.
The sensitivity of anti-SSA and anti-SSB antibodies in 
whole saliva was 49% and 29%, respectively, and the 
specificity was 87.5% and 95%, respectively. The sen-
sitivity of anti-SSA and anti-SSB antibodies in parotid 
saliva was 32% and 8%, respectively, and the specifi-
city was 95.52% and 97.86%, respectively (Table 1). The 
n. WS anti-SSA 
positive patients (%) 
n. WS anti-SSB 
positive patients (%) 
n. PS anti-SSA positive 
patients (%) 
n. PS anti-SSB positive 
patients (%) 
pSS (n=100) 49 (49*) 29 (29*) 32 (32*) 8 (8) 
SLE (n=40) 11 (27.5) 4 (10) 5 (12.5) 2 (5) 
RA(n=40) 5 (12.5) 2 (5x`) 2 (5) 1 (2.5) 
HC(n=60)               2 (3.3) 0 (0)    1 (1.7) 0 (0) 
Table 1.  Prevalence of anti-SSA/B antibodies in whole saliva (WS) and parotid saliva (PS) in different groups.
*p<0.05 compared with other groups. (pSS =primary Sjögren’s síndrome, SLE=systemic lupus erythematous, RA=rheumatoid arhtritis, 
HC=healthy control).
Anti-SSA
p-value
Anti-SSB 
p-value
+ - + - 
Saliva flow rate (mean) (ml/10min) 0.492 0.216 0.020* 0.403 0.245 0.233 
Schirmer’s test + 47 50 0.534 28 69 0.876 - 2 1 1 2 
Tear film break-up test + 45 42 0.159 26 61 0.614 - 4 9 3 10 
Corneal staining test + 29 26 0.410 17 38 0.642 - 20 25 12 33 
Parotid sialography 
examinations 
+ 30 24 0.220 18 37 0.364 
- 19 27 11 34 
Table 2. Comparison of clinical features in pSS patients with and without whole saliva anti-SSA/B antibodies.
*p<0.05 compared with whole saliva anti-SSA negative group.
prevalence of anti-SSA/B antibodies in whole saliva 
was significantly higher than in parotid saliva (p<0.05). 
The agreement between whole and parotid saliva anti-
SSA was high, with a kappa value of 0.617 (p<0.05).
3. Correlation between clinical features and anti-SSA/B 
antibodies.
There was a significant difference in the saliva flow rate 
between whole salivary anti-SSA-positive pSS patients 
and anti-SSA-negative pSS patients (p<0.05), whereas 
no significant differences were found in the other clini-
cal parameters, including Schirmer’s test, the tear film 
break-up test, the corneal staining test, and parotid 
sialography examinations (all p>0.05) (Table 2).
4. Correlation between laboratory parameters and anti-
SSA/B antibodies.
The positive rate of elevated IgG in whole salivary anti-
SSA-positive pSS patients was significantly higher than 
in anti-SSA-negative pSS patients (p<0.05). The posi-
tive rates of RF and ANA in SSB-positive pSS patients 
were significantly higher than in the SSB-negative pSS 
patients (p<0.05) (Table 3). In the pSS group, the diag-
nostic accuracy of anti-SSA/B antibodies in whole sa-
liva was significantly lower than in serum (p<0.05). The 
agreement between serum and whole salivary anti-SSA 
was moderate, with a kappa value of 0.465 (p<0.05). 
The agreement between serum and whole salivary anti-
SSB was high, with a kappa value of 0.720 (p<0.05).
Discussion
The expression of specific autoantibodies in the serum 
of patients with pSS is thought to be of great diagnostic 
value, with anti-SSA/B antibodies being the most rep-
resented (16). The prevalence of SSA and SSB ranged 
from 13-73% in the serum of patients with pSS (1). 
Compared to serum, the collection of saliva is noninva-
sive and convenient. Saliva is a potential tool for diag-
nosing SS. Because pSS mainly targets exocrine glands, 
salivary glands are directly and strongly influenced. As 
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a result, the saliva test might have value in diagnosing 
the disease.
A decrease in saliva flow rate is a clinical characteris-
tic of pSS, but the possible changes in the salivary con-
stituents, such as SSA/B, are still unknown. Recently, 
researchers have detected several autoantibodies ex-
pressed in the saliva of patients with pSS, such as anti-
alpha-fodrin, anti-M3R, and anti-SSA/B antibodies (17-
19). Their roles in the diagnosis of SS have also been 
assessed. Sreebny (20) has studied the expression of 
anti-SSA/B antibodies in stimulated mixed saliva from 
13 patients with SS, and reported that 46.15% were pos-
itive for salivary antibodies, with a specificity of 100%. 
However, the limitations of these studies, such as small 
sample size, and possible leakage of whole saliva, limit 
their value in determining the role of saliva testing in 
the diagnosis of SS.
Our study included 100 patients with pSS and 140 (60 
healthy controls and 80 controls with other rheumatic 
diseases) controls. SSA/B antibodies were examined in 
both whole saliva and parotid saliva using ELISA. In the 
pSS group, the sensitivity of anti-SSA and anti-SSB an-
tibodies in whole saliva was 49% and 29%, respectively, 
and the specificity was 87.5% and 95%, respectively. 
The sensitivity of anti-SSA and anti-SSB antibodies in 
parotid saliva was 32% and 8%, respectively, and the 
specificity was 95.52% and 97.86%, respectively. In the 
pSS group, the diagnostic accuracy of anti-SSA/B anti-
bodies in whole saliva was significantly higher than in 
parotid saliva (p<0.05), but was significantly lower than 
in serum (p<0.05). The positive rate of salivary SSB 
was about 29%, with a poor correlation to serum SSB 
levels. Further studies are needed to interpret this re-
sult. Our results suggest that serum is significantly more 
sensitive than either whole or parotid saliva for detect-
ing SSA/B. All patients who were positive for SSA/B 
in mixed saliva and parotid saliva also had serum that 
tested positive. Based on our results, serum leakage in 
mixed saliva seems to be the most likely explanation for 
the comparatively higher positivity in mixed saliva than 
parotid saliva.
Hammi et al. (21) studied anti-ENA antibody in parotid 
saliva and serum from 40 patients with SS, and reported 
that the positive rate of anti-ENA antibodies in serum 
was much higher than in parotid saliva. All of the pa-
tients with positive parotid salivary anti-ENA also had 
positive serum anti-ENA. Our findings are consistent 
with the study by Hammi et al. (21), which suggests a 
higher sensitivity and specificity of serum anti-ENA 
than saliva. Given the ease of collecting mixed saliva 
and the comparatively greater sensitivity and specificity, 
the use of whole salivary anti-ENA measurement in the 
diagnosis of SS is more practical than parotid saliva.
In comparing the clinical features of pSS patients 
with and without whole salivary anti-SSA/B antibod-
ies, we found that the salivary flow rate in anti-SSA-
positive pSS patients was significantly lower than in 
anti-SSA-negative pSS patients, whereas no significant 
differences were found in the Schirmer’s test, the tear 
film break-up test, the corneal staining test, or parotid 
sialography examinations between anti-SSA-positive 
and anti-SSA-negative pSS patients. Atkinson et al. 
(22) reported that anti-SSA and anti-SSB antibodies 
can bond to normal parotid tissue by recognizing SSA/
Ro and SSB/La antigens. Recently, Takada et al. (23) 
reported that the salivary flow rate in subjects with any 
of the antibodies associated with sicca (e.g., ACA, anti-
SSA, anti-SSB) decreased with age. These results, com-
bined with our findings imply that anti-SSA antibodies 
are possible to contribute to the salivary gland dysfunc-
tion. However, no differences were found in the clini-
cal features of anti-SSB-positive and anti-SSB-negative 
pSS patients, which might be attributed to the very low 
positive rate of whole salivary anti-SSB antibodies in 
the participants.
In comparing the laboratory parameters in pSS patients 
Anti-SSA
p-value
Anti-SSB 
p-value
+ - + - 
Serum anti-SSA + 48 26 0.000* 29 45 0.000*- 1 25 0 26 
Serum anti-SSB + 26 7 0.000* 25 8 0.000*- 23 44 4 63 
ANA + 8 10 0.669 25 8 0.000*- 41 41 4 63 
RF
+ 10 9 
0.725 
10 9 0.012*- 39 42 19 62 
Elevated C3 + 5 9 0.284 1 13 0.052 - 44 42 28 58 
Elevated immunoglobulin G + 47 42 0.030* 27 62 0.402 - 2 9 2 9 
* p<0.05 compared with whole saliva anti-SSA/B negative group; ** ANA - antinuclear factor; *** 
RF - rheumatoid factor.
Table 3. Comparison of laboratory parameters in pSS patients with and without whole saliva anti-
SSA/B antibodies.
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with and without whole salivary anti-SSA/B antibodies, 
we found that three laboratory parameters were signifi-
cantly (p<0.05) higher in anti-SSA-positive patients than 
in anti-SSA-negative patients; namely, serum anti-SSA, 
serum anti-SSB, and immunoglobulin G. In addition, 
four laboratory parameters were significantly higher in 
pSS patients with than in those without anti-SSB anti-
bodies; namely, serum anti-SSA, serum anti-SSB, ANA, 
and RF. Our findings were partially consistent with Al-
exander et al. (10), who detected anti-SSA and anti-SSB 
antibodies more frequently in patients with RF, polyclo-
nal hypergammaglobulinemia, and cryoglobulinemia. 
These results suggested that in the salivary anti-SSA/B 
positive pSS patients, hyper-immunoglobulin G, posi-
tive serum ANA and RF are more frequent. In addition, 
significant correlations were found between saliva and 
serum SSA/B, which suggests the suitability of whole 
salivary SSA in the diagnosis of SS.
The ELISA IgG kit was the only method used to ana-
lyze salivary anti-SSA and anti-SSB in our study. Oth-
er methods, such as immunodot and ELISA IgA kit, 
should be investigated, as they might have the potential 
to improve the sensitivity and specificity for salivary 
anti-SSA and anti-SSB antibodies.
In summary, the sensitivity and specificity of SSA/B in 
mixed saliva from patients with pSS was not as high as 
in serum. The positive rate of SSA/B in parotid saliva 
was significantly lower than in mixed saliva, whereas 
both had similar specificity, which is consistent with 
serum antibodies. Compared to parotid saliva, whole 
saliva is more suitable as a diagnostic fluid. Using sali-
vary anti-SSA/B antibodies as a single test seems to be 
insufficient, given the relatively low sensitivity. Future 
studies should investigate the possibility of combining 
tests for different salivary autoantibodies as a method 
for diagnosing pSS.
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